Welcome to our dedicated page for Biohaven Ltd. news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven Ltd. stock.
Biohaven Ltd. (NYSE: BHVN) is a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of transformative treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Leveraging multiple proprietary drug development platforms, Biohaven is advancing an impressive product pipeline that addresses a variety of diseases, ranging from neuromuscular and metabolic disorders to antibody-drug conjugates for cancer and obsessive-compulsive disorder.
Biohaven's notable product candidates include:
- Glutamate Modulation: Troriluzole, currently in Phase 3 trials for obsessive-compulsive disorder, offers hope for patients with inadequate responses to standard treatments.
- Myostatin Inhibition: Taldefgrobep alfa, in Phase 3 studies for spinal muscular atrophy and being evaluated for obesity treatment, targets muscle growth regulation pathways.
- Ion Channels: BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, is in clinical development for epilepsy and mood disorders.
- Inflammation & Immunology: BHV-1300 and BHV-1310, from the innovative extracellular protein degradation platform, aim to treat autoimmune diseases by lowering IgG levels.
- Oncology: BHV-1510, a Trophoblast Cell Surface Antigen-2 (Trop-2) directed ADC, shows promise in treating select advanced epithelial tumors.
Recent milestones highlighted at the 42nd Annual J.P. Morgan Healthcare Conference and other events include significant progress in these areas and the initiation of pivotal human studies. CEO Dr. Vlad Coric emphasized the company's strong focus on neuroscience, immunology, and oncology, with near-term potential in these fields.
Financial updates reveal solid funding for future advancements, supported by a public offering that raised $230 million. Biohaven's robust clinical and preclinical pipelines are backed by an experienced leadership team and a strong financial foundation, underlining the company's capacity for rapid, efficient drug development.
The company’s leadership in neuroscience was underscored at the 2024 American Academy of Neurology Annual Meeting, featuring multiple presentations on Kv7 ion channel modulation, MoDEs, TRPM3 antagonism, and TYK2/JAK1 inhibition. Looking ahead, Biohaven is poised for a groundbreaking year, with multiple INDs planned and significant clinical data expected across its portfolio.
For more information, visit Biohaven's website.
Biohaven Pharmaceutical (BHVN) announced 13 abstracts at the 2022 AAN annual meeting, showcasing advancements in migraine treatment. Key findings include a significant reduction in opioid prescriptions post-Nurtec ODT treatment and positive Phase 1 results for intranasal zavegepant, indicating its safety at doses up to 40 mg. Additionally, systematic reviews confirmed rimegepant, atogepant, and monoclonal antibodies as effective migraine prevention options. These innovations underscore Biohaven's commitment to improving outcomes for patients with neurological conditions.
Biohaven Pharmaceutical (BHVN) announced its fourth-quarter and full-year 2021 financial results, revealing a transformative year with $463 million in net revenue from NURTEC ODT. The company signed a $1.2 billion global commercialization agreement with Pfizer for rimegepant and zavegepant, propelling NURTEC ODT to market leadership. Q4 revenue reached $190 million, marking a 441% increase year-over-year. Despite significant growth, Biohaven incurred a net loss of $199.2 million. The company anticipates continued momentum in 2022 with multiple product developments and market expansions.
Biohaven and Pfizer have received a positive opinion from the CHMP for rimegepant, a new treatment for migraines, recommending its 75 mg dose for both acute and preventive use in adults. This marks a significant advancement, as rimegepant is set to become the first oral CGRP receptor antagonist in the EU under the trade name VYDURA™, pending European Commission approval. The CHMP's recommendation was based on results from multiple Phase 3 studies that demonstrated rimegepant's safety and efficacy in treating migraines, addressing a crucial unmet need for patients.
Biohaven Pharmaceutical (NYSE: BHVN) announced its acquisition of Channel Biosciences, enhancing its neuroscience portfolio with the Kv7 channel targeting platform. The lead asset, BHV-7000, aims to address epilepsy, a condition affecting over 3.5 million Americans. The deal involves an upfront payment of $65 million in shares and $35 million in cash, along with potential earnouts up to $1.2 billion based on developmental and sales milestones. This strategic move aims to leverage Biohaven's commercial capabilities and deliver innovative treatment options for patients with epilepsy.
Biohaven Pharmaceutical announced a worldwide licensing agreement with Bristol Myers Squibb for the development of taldefgrobep alfa, a Phase 3-ready anti-myostatin adnectin targeted at treating Spinal Muscular Atrophy (SMA). This is Biohaven's third license from Bristol Myers Squibb, with the trial expected to commence in 2022. Taldefgrobep aims to enhance muscle mass and strength in patients with neuromuscular diseases, representing a potential breakthrough in treatment strategies. The agreement includes milestone payments and sales-based royalties for Bristol Myers Squibb.
Biohaven Pharmaceutical (NYSE: BHVN) has initiated a Phase 2/3 clinical trial to evaluate the safety and efficacy of Nurtec® ODT (rimegepant) 75 mg in treating chronic rhinosinusitis (CRS), impacting 5-12% of the population. The trial aims to enroll 200 patients across 25 U.S. sites and will assess changes in facial pain and safety measures. Nurtec ODT is already FDA-approved for migraine treatment. The trial represents a potential new therapeutic option for patients suffering from this condition, addressing a significant unmet medical need in CRS management.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will host its fourth quarter and year-end 2021 earnings call on February 25, 2022, at 8:30 a.m. ET. The call will provide financial results for the quarter ending December 31, 2021, alongside recent accomplishments and upcoming milestones. Biohaven is focusing on innovative therapies for neurological and neuropsychiatric diseases, including FDA-approved NURTEC ODT for migraine treatment and a wide pipeline targeting various conditions. For participation, call 877-407-9120 (domestic) or 412-902-1009 (international).
Biohaven Pharmaceutical and Pfizer announced successful Phase 3 trial results for rimegepant, aimed at treating migraines in 1,431 adults across the Asia-Pacific region. This trial, led by BioShin Limited, confirmed that a single 75 mg dose significantly alleviated migraine symptoms within two hours (p<0.0001) and showed sustained effectiveness for up to 48 hours. Following this success, rimegepant, currently marketed as Nurtec ODT in the U.S., has regulatory applications pending in Europe. The partnership aims to expand the drug's availability, particularly in regions where migraine remains prevalent.
Biohaven Pharmaceuticals partners with Hardware LDN at New York Fashion Week to raise awareness about migraines, affecting nearly 40 million Americans. Designer Jessica Horwell showcases a new collection featuring a classic bomber jacket promoting the word "Fearless," while four models living with migraine walk the runway. Biohaven highlights its migraine treatment, Nurtec ODT, effective in managing symptoms. The collaboration aims to empower women to advocate for better treatment options and supports public awareness regarding the impact of migraines.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) published findings in Cephalalgia Reports indicating that the long-term treatment of migraines with rimegepant 75 mg significantly reduced migraine frequency. The study involved 1,044 patients undergoing a 52-week Open Label Safety Study (BHV3000-201). Results showed a greater reduction in monthly migraine days (MMD) as patients continued with treatment, particularly in those with lower baseline MMD. The acute treatment, first FDA-approved in February 2020, highlights rimegepant's potential both for immediate relief and long-term therapeutic benefits.
FAQ
What is the current stock price of Biohaven Ltd. (BHVN)?
What is the market cap of Biohaven Ltd. (BHVN)?
What does Biohaven Ltd. specialize in?
What are some of Biohaven's key product candidates?
What recent milestones has Biohaven achieved?
How is Biohaven funded for its future projects?
What is Biohaven's approach to treating autoimmune diseases?
Where can I find more information about Biohaven's clinical trials?
Who leads Biohaven Ltd.?
What are the primary therapeutic areas Biohaven is focusing on in 2024?
What recent events highlight Biohaven's advancements in neuroscience?